Pharmacotherapeutic group
Antitumor drug, antibiotic
ATX code
L01DB01
Pharmacodynamics: Antitumor antibiotic of the anthracycline series isolated from a culture of Streptomyces peucetius var. caesius.
It has antimitotic and antiproliferative effects. Mechanism of action is in interaction with DNA forming free radicals and direct effect on cell membranes with inhibition of nucleic acids synthesis. Cells are sensitive to the drug in S- and G2-phases.
Pharmacokinetics: Absorption – high distribution – relatively uniform. Across the blood-brain barrier does not penetrate. Binding with plasma proteins is about 75%. It is metabolized in the liver to form active metabolite doxorubicinol. Enzymatic reduction of doxorubicin under the influence of oxidase reductases and dehydrogenases leads to the formation of free radicals, which may contribute to the cardiotoxic effect. After IV administration it rapidly disappears from the blood concentrating in the liver kidneys myocardium spleen lungs. Half-life is 20-48 h for doxorubicin and doxorubicinol. Excretion: with the bile – 40% unchanged for 7 days with the urine – 5-12% of doxorubicin and its metabolites for 5 days.
Indications
Active ingredient
Composition
Each vial contains
The active ingredient:
doxorubicin hydrochloride 10 mg.
The excipients:
Mannitol.
How to take, the dosage
Interaction
Special Instructions
Contraindications
Side effects
Overdose
Pregnancy use
Weight | 0.020 kg |
---|---|
Shelf life | 2 years. Do not use after the expiration date stated on the package. |
Conditions of storage | List A. In a dry, dark place out of the reach of children at a temperature not exceeding + 5 ° C. |
Manufacturer | Bryntsalov-A PJSC, Russia |
Medication form | lyophilizate |
Brand | Bryntsalov-A PJSC |
Related products
Buy Doxorubicin-Ferein, lyophilizate 10 mg with delivery to USA, UK, Europe and over 120 other countries.